Recent Headlines
Within Biotechnology
Breaking Barriers: ALS TDI Unveils Groundbreaking ALS Research Collaborative (ARC) to Accelerate Global Research in ALS
The ALS Research Collaborative will revolutionize ALS research by providing scientists with unprecedented access to the data and tools they need to discover new treatments and accelerate progress toward cures for ALS. - March 15, 2023 - ALS Therapy Development Institute
New Research Identifies Latest Clinical Development and CRO Outsourcing Trends in China
Groundbreaking Research Explores the Chinese Innovative Biopharmaceutical Clinical Development Market, CRO Outsourcing and Future Growth with Over 100 Chinese Biopharma Professionals - March 15, 2023 - Life Science Strategy Group, LLC
Creative Diagnostics Introduces Microneutralization Assay Service for Virus Detection
Creative Diagnostics recently introduced the Microneutralization Assay Service to support research labs in detecting virus-specific neutralizing antibodies from human and animal sera. - March 12, 2023 - Creative Diagnostics
Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research
Creative Diagnostics recently introduced comprehensive contract ELISA kit development services to the R&D and IVD communities. - March 12, 2023 - Creative Diagnostics
NuvOx Newly Issued US Patent
NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, announced that it has been issued US Patent No. 11,571,467, “Dodecafluoropentane emulsion (DDFPe) as a stroke and ischemia... - March 02, 2023 - NuvOx Pharma
Creative Diagnostics Introduces TCID50 Assay Service for Determining Viral Titers
Creative Diagnostics recently introduced the TCID50 Assay Service suitable for drug sensitivity tests, infectious units quantification, the determination of virus doses, as well as virus release studies. - February 17, 2023 - Creative Diagnostics
Creative Diagnostics Launches HPV L1 Antibodies for Neutralization and Vaccine Development
Creative Diagnostics recently introduced a series of HPV vaccine development products. - February 17, 2023 - Creative Diagnostics
DistillerSR Launches Industry's Most Comprehensive and Configurable PRISMA 2020 Flow Diagram Reporting Module
DistillerSR® Inc., the market leader in AI-enabled literature review automation software and creator of DistillerSR™, today announced the launch of full support for the PRISMA 2020 report guidelines. DistillerSR’s PRISMA 2020 flow diagram reporting module enables research... - January 31, 2023 - DistillerSR
Zifo R&D Solutions Announces Acquisition of beyontics GmbH
Zifo, a leading global specialist scientific informatics services provider, announces the acquisition of beyontics™. A scientific service provider, beyontics has extensive experience in selecting, configuring, optimizing, and supporting Chromatography Data Systems (CDS), particularly the... - January 19, 2023 - Zifo
Genesis AEC Celebrates 25th Anniversary
Leading AEC firm’s milestone includes 8,300+ projects for 600+ life sciences leaders nationwide. - January 18, 2023 - Genesis AEC
Newly Available Horse-Side IgG Test Requires No Refrigeration
VMRD, Inc is excited to share the launch of their latest offering for equine veterinarians, a novel horse-side test to measure IgG in foals. - January 17, 2023 - VMRD, Inc.
End the Legacy, Dedicated to Providing Resources to and Advocating for the Genetic ALS and FTD Community, Presenting to FDA January 12
Individuals impacted by hereditary ALS and FTD announce the establishment of a nonprofit organization dedicated to supporting and advocating for their community, Genetic ALS & FTD: End the Legacy. ALS and FTD are neurodegenerative diseases. ALS affects the motor system and leads to rapidly... - January 10, 2023 - Genetic ALS & FTD: End the Legacy
Huntington Study Group Names First Chief Innovation Officer
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, today announced Brett Kinsler has been named to the newly created position of Chief Innovation Officer (CINO). - January 10, 2023 - Huntington Study Group
Creative Diagnostics Expands Its Monoclonal Antibodies Offering to Customers
Creative Diagnostics expanded its monoclonal antibodies capabilities and offerings to global customers. - January 06, 2023 - Creative Diagnostics
Creative Diagnostics Introduces New Hemagglutination Inhibition Assay Services
Creative Diagnostics recently introduced Hemagglutination Inhibition Assay services to determine relative concentrations of viruses, bacteria, or antibodies. - January 06, 2023 - Creative Diagnostics
Creative Diagnostics Introduces Plaque Reduction Assay Service for Research Applications
Creative Diagnostics recently introduced Plaque Reduction Assay services to detect antibodies from testing serum and viruses within diseased materials to diagnose viral infectious diseases. - December 28, 2022 - Creative Diagnostics
Creative Diagnostics Launches Anti-Bacterial Antibodies to Support Autoimmune Diseases Research
Creative Diagnostics announced the launch of several mouse antibacterial monoclonal antibodies for the development of human and mouse anti-bacterial antibody detection kits. - December 28, 2022 - Creative Diagnostics
Paras Biopharmaceuticals Creates Excellence with “Continuous Biomanufacturing”: Achieves Objectives of “High Productivity & Biomanufacturing Innovation”
With 6 years of dedicated work at Paras Biopharmaceuticals and the use of Paras Biopharmaceuticals’ unique technology platform (which comprises of Bioproduction technologies for economical production of biologics), the company is pleased to announce that an excellent scale-up production process is achieved with “Continuous Biomanufacturing.” - December 19, 2022 - Paras Biopharmaceuticals Finland Oy
Paras Biopharma Streamlines Offerings as “Biologics CDMO” and Biosimilar Co-Development as “Paras Biologics”
Paras Biopharmaceuticals Finland Oy today revealed that the company has streamlined and enhanced its business activities with the establishment of a division called, Paras Biologics. In addition to its existing biologics CDMO activities and capabilities (this division is now referred to as Paras Biopharma), the creation of Paras Biologics enhances the company’s biologics and biosimilar pipeline for co-development and licensing opportunities. - December 11, 2022 - Paras Biopharmaceuticals Finland Oy
PharmStars Announces Fall 2022 Accelerator Graduates: 11 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program
PharmStars, the pharma-focused accelerator for digital health startups, announces the graduation of 11 startups from its Fall 2022 program focused on “Innovations in Real-World Evidence.” The graduating startups successfully completed PharmaU, PharmStars’ 10-week education, and mentoring program. PharmaU culminated with a Showcase Event--held in Boston in early November--that brought together the participating startups and PharmStars’ seven innovation-minded pharma members. - December 08, 2022 - PharmStars
PharmStars Announces “Innovations in Women’s Health and Health Equity” Theme for Spring 2023 Accelerator
PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its Spring 2023 cohort with the theme “Digital Innovations in Women’s Health and Health Equity.” Startups with digital innovations that promote more equitable, inclusive healthcare for underserved population or focused on women’s health (e.g., breast, ovarian, and cervical cancer; gynecological conditions; osteoporosis; menopausal, hormonal, and reproductive conditions) are welcome to apply. - December 05, 2022 - PharmStars
Clinical Research Organization, Huntington Study Group “Firsts” Continue
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD) through its Clinical Research Organization (CRO), HSG Clinical Research, Inc. (HSGCR) continues making groundbreaking progress in the HD world. At their Annual Meeting in November, the... - December 05, 2022 - Huntington Study Group
Paras Biopharmaceuticals Finland Oy is Highly Recommended for Biologics CDMO – Development / Scale-up & Production of Biologics by Innovative USA Biopharma Company
Paras Biopharmaceuticals is pleased to announce that the company has been highly recommended for its Biologics CDMO – development / scale-up and production capabilities. The Paras Biopharmaceuticals Team has successfully completed multiple biologics projects in 2022. - November 29, 2022 - Paras Biopharmaceuticals Finland Oy
Huntington Study Group Annual Meeting
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD), recently held its 29th Annual Meeting in Tampa, FL. This renowned meeting brings together HD thought leaders, scientific experts, industry partners and sponsors, advocacy groups, and... - November 29, 2022 - Huntington Study Group
Creative Diagnostics Announces New Polyethylene Glycol Antibodies Detection Kits
Creative Diagnostics announced the launch of a panel of anti-PEG IgG or IgM ELISA kits with different species reactivity to detect anti-PEG IgG or IgM in serum and plasma. - November 26, 2022 - Creative Diagnostics
Creative Diagnostics Introduces Hemagglutination Assay Service for Scientific Applications
Creative Diagnostics recently introduced Hemagglutination Assay services for influenza vaccine, diagnostic, and surveillance communities to measure virus and antibody titers and monitor influenza subtypes. - November 26, 2022 - Creative Diagnostics
David Lim Joins the Team at Microvascular Therapeutics as Director of Finance
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of David Lim as Director of Finance at MVT. Mr. Lim brings a broad experience with the business development and strategic financing for diagnostic pharmaceuticals across all... - November 25, 2022 - Microvascular Therapeutics, Inc.
Marty Rosenberg joins the Board of Scientific Advisors at Microvascular Therapeutics.
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Marty Rosenberg to the MVT Board of Scientific Advisors. Mr. Rosenberg brings a broad experience with the clinical development and global regulatory approval process for... - November 25, 2022 - Microvascular Therapeutics, Inc.
Microvascular Therapeutics Receives Funds from the National Cancer Institute (NCI) for Its Brain Tumor Program
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Cancer Institute (NCI). Emmanuelle Meuillet, Chief Scientific and Operating Officer at MVT said, “We are... - November 18, 2022 - Microvascular Therapeutics, Inc.
Prosel Bioscience Becomes One Cell Foods and Names Dr. Scott Jenkins Its New CEO
One Cell Food, Inc will focus on scaling its proprietary bioreactor design to commercialize developed strains for its first food product by early 2023. As the new CEO, Dr. Scott Jenkins will lead the operation and fundraising efforts. - November 17, 2022 - One Cell Foods, Inc.
PharmStars Announces Fall 2022 Startup Showcase Event
PharmStars, the pharma-focused accelerator for digital health startups, announces that its Fall 2022 Showcase Event will begin on November 8, 2022. The Showcase is the culmination of a 10-week startup accelerator program. At the Showcase Event, startups will make formal presentations to and meet... - November 08, 2022 - PharmStars
Biomed Industries, Inc. (“Biomed”) Today Announced the Closing of Its Merger with MedAware Systems, Inc., (“MedAware”)
Biomed Industries, Inc. (“Biomed”) today announced the closing of its merger with MedAware Systems, Inc., (“MedAware”), in which all issued and outstanding common shares of capital stock of MedAware will be exchanged for common stock of Biomed at a ratio of 5.33 shares of MedAware for 1 new common share of Biomed. The transaction valued at an aggregate of $20 million, to be paid by 2,259,170 common shares of Biomed. At present, Biomed has approximately 76,354,075 common shares issued. - November 07, 2022 - Biomed Industries, Inc.
Thrivous Launches Vitality Geroprotector Formula 2
Thrivous, the human enhancement company, has released Vitality Geroprotector Formula 2 with Mirtoselect® Blueberry Anthocyanin. Vitality is the advanced geroprotector supplement that Thrivous develops to enhance metabolism and cell function for better aging. Vitality combines geroprotector... - November 07, 2022 - Thrivous
New Pivotal Data Demonstrates Clinical Feasibility of GeneFluidics’ Direct-from-Specimen AST in Clinical Settings
GeneFluidics, Inc. is pleased to announce a joint publication with the Medical College of Wisconsin (MCW) that introduces rapid antimicrobial susceptibility testing (AST), which would represent a paradigm shift in the clinical management of microbial infections. The data from the MCW study have... - November 04, 2022 - GeneFluidics Inc.
Pharma/Vaccine Exec Brad Thompson Joins Fuld & Company as Advisory Board Member
Fuld & Company welcomes Pharma/Vaccine Exec Brad Thompson as an Advisory Board Member. Brad brings over twenty years of experience building franchise and brand strategies in the vaccine and pharmaceutical space. He will be an instrumental member of Fuld's HLS team to help propel the success of the company's pharma and biotech clients. - November 03, 2022 - Fuld & Company
DistillerSR Launches New CuratorCR Capabilities to More Dynamically Manage and Reuse Evidence-Based Research
CuratorCR Knowledge Center Provides Alternative to Elsevier’s QUOSA Virtual Library as Its Sunset Date Looms. - October 31, 2022 - DistillerSR
Gallant Announces Hiring of John Klacking, Ph.D. as Chief Business Officer
Furthering its regenerative medicine therapeutics research and development, animal biotech company Gallant welcomes a pioneer in the biotech space. - October 25, 2022 - Gallant
Huntington Study Group Announces Results from the HD-Net Assessment on the State of Care for Huntington’s Disease in the United States
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce the results from the novel HD-Net survey, which examined the United States Huntington’s disease (HD) care delivery in a variety of clinic settings by HD specialists and non-specialists. - October 25, 2022 - Huntington Study Group
Minus K Technology Announces Announces Its Seventh U.S. Educational Giveaway of Vibration Isolators to Colleges and Universities
As Minus K celebrates their upcoming 30 years in business, they are giving away $25,000* dollars worth of passive mechanical patented superior performing negative-stiffness low-frequency vibration isolators to colleges in the United States. - October 25, 2022 - Minus K Technology Inc.
Vivisum Partners Publishes Strategic Analysis on the Ulcerative Colitis Marketplace
Among branded ulcerative colitis treatments, 84% of US gastroenterologists expect Zeposia to see an increase in prescription volume over the next 12 months, according to new research on the ulcerative colitis marketplace published by Vivisum Partners. Vivisum Partners has just published its... - October 25, 2022 - Vivisum Partners, LLC
New Market Insights on the Best MS Treatment Published by Vivisum Partners
What’s the best MS treatment according to neurologists? The question of how to assess the ideal drug to treat multiple sclerosis is difficult to answer. Neurologists determine which clinical attributes take higher priority for each patient. Vivisum Partners, LLC, a market research firm in... - October 24, 2022 - Vivisum Partners, LLC
Creative Diagnostics Introduces Fluorometric Neuraminidase Assay Service for High-Throughput Discovery
As an expert in the antiviral field providing solutions to assist virology and microbiology research, Creative Diagnostics recently introduced Fluorometric Neuraminidase Assay services to the global research community, suitable for functional detection of NI-resistant viruses in mixed virus... - October 23, 2022 - Creative Diagnostics
Creative Diagnostics Launches Monkeypox Virus Antigens and Antibodies to Accelerate MPXV Study
Creative Diagnostics announced the launch of Monkeypox Virus Antigens and Antibodies to support scientists focused on the research of monkeypox virus. - October 23, 2022 - Creative Diagnostics
Huntington Study Group Announces myHDstory™ Pilot Study: Making HD Voices Heard Has Reached Target Enrollment
The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce that the pilot study, Making HD Voices Heard, on the new online research platform, myHDstory™, has reached its enrollment target. “The HSG... - October 18, 2022 - Huntington Study Group
Biolexis Therapeutics Announces Launch of FIELDS, an AI/ML Drug Discovery Platform
Biolexis is the first company to combine a curated historical wet-lab database, including half-a-million targets of binding data points, with an automated AI/ML-augmented discovery platform. - October 14, 2022 - Biolexis Therapeutics Inc.
Thrivous Releases Serenity Nightly Nootropic Formula 3
Thrivous, the human enhancement company, has released Serenity Nightly Nootropic Formula 3 with KSM-66® Ashwagandha. Serenity is the advanced nootropic supplement that Thrivous develops to enhance relaxation, sleep, and next-day focus. Serenity combines nootropic nutrients with the highest... - October 14, 2022 - Thrivous
Huntington Study Group Enrolls First Participant for Its Observational Study to Test the Reliability of the Virtual Use of the Unified Huntington’s Disease Rating Scale
The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD) for over 30 years, together with its Clinical Research Organization (“CRO”), the HSG Clinical Research, Inc., today announces the enrollment of the first participant of its... - October 12, 2022 - Huntington Study Group
Mirror Biologics, Inc. Announces Additional $20 Million Investment to Close Out $30 Million Series A Investment Round
Mirror Biologics, Inc., a clinical stage biopharmaceutical company today announced the completion of the final $20 million tranche of its $30 million Series A investment round with Bradbury Asset Management (Hong Kong), Limited. Bradbury provided an initial $10 million tranche for this round in... - October 11, 2022 - Mirror Biologics, Inc.
SYNG Pharmaceuticals Announces Issuance of Its Canadian Patent for Non-Hormonal Therapy for Endometriosis
SYNG Pharmaceuticals Inc. (SYNG), a Kingston, Ontario based women’s health biotech, is pleased to announce that on October 04, 2022, the Canadian Intellectual Property Office granted Canada Patent No. 2,903,608 titled, "Treatment of endometriosis, angiogenesis and/or endometrial lesion growth." - October 09, 2022 - SYNG Pharmaceuticals Inc.
Vivisum Partners' Research Finds New Ulcerative Colitis Drugs Provide Excitement to Gastroenterologists
Newly published research found that several new ulcerative colitis drugs currently in development are providing excitement among gastroenterologists eager to add additional medicines to their current treatment options. Based on a market analysis from Vivisum Partners, a market research and brand... - October 08, 2022 - Vivisum Partners, LLC